9.02 USD
▲-0.17+2.38%
盘后 8.91 +1.14%
2026-08-03
市值
$2.29B
市盈率
—
EPS
-2.10
股息率
—
52 周区间
6.00 – 11.22
成交量
2.92M
Beta
0.54
目标价
21.00
52W 低 6.0052W 高 11.22
价格走势
公司简介
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein i...